30 June 2022 in Frontiers in Pharmacology
Background: Jaranol has shown a wide range of pharmacological activities; however, no study has yet examined in vivo toxicity. The study aimed to investigate the oral acute and sub-acute toxicity of jaranol in mice.Methods: The acute toxicity was determined by a single oral dose of jaranol (2000 mg/kg). Therein animal behaviour and mortality rate were observed for 14 days. The jaranol (50, 100 and 200 mg/kg BW·d−1) was given by gavage for 28 days daily in the sub-acute study. The mouse body weight (BW), organ weight, food, water intake, biochemical, haematological parameters, and histopathology were studied in acute and sub-acute toxicity.Results: During the acute toxicity test, a single oral dose (2000 mg/kg) jaranol did not cause significant alteration in majority of the hematological indices. However, jaranol decreased the level of serum alanine aminotransferase and aspartate aminotransferase. Those results showed that the oral lethal dose 50 (LD50) of jaranol was higher than 2000 mg/kg BW, regardless of sex. In repeated daily oral doses (50, 100 and 200 mg/kg BW·d−1), no mortality was recorded in the various experimental groups. The jaranol reduced body weight gain (200 mg/kg BW·d−1), the relative spleen weight (all doses) and serum alanine aminotransferase activity (200 mg/kg BW·d−1). On the other hand, jaranol significantly elevated red blood cell count (100 and 200 mg/kg BW·d−1) and serum creatinine levels (200 mg/kg BW·d−1). Histological study revealed that spleen bleeding was identified in 200 mg/kg jaranol-treated mice.Conclusion: Jaranol was relatively safe in Kunming Mice when repetitively administered orally in small doses for a prolonged period of time. We recommend more chronic toxicity studies and clinical trials on jaranol to ensure that its use is free of potential toxicity to humans.
3 July 2023 in Biomolecules and Biomedicine
In this study, we aimed to compare survival outcomes after receiving radiofrequency ablation (RFA) and hepatic resection (HR) for solitary hepatocellular carcinoma (HCC) with stratification by tumor size and age. A retrospective cohort was obtained from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015. Patients were grouped by tumor size (0-2, 2-5, and > 5 cm) and age (>65 and ≤65). Overall survival (OS) and disease-specific survival (DSS) were assessed. For patients >65 with tumors measuring 0-2 and 2-5 cm, the HR group had better OS and DSS compared with the RFA group. For patients >65 with tumors > 5 cm, OS and DSS did not differ significantly between the RFA and HR groups (p = 0.262 and p = 0.129, respectively). For patients ≤65, the HR group had better OS and DSS compared with the RFA group regardless of tumor size. For patients with resectable solitary HCC, regardless of age, HR is the better choice not only for tumors ≤ 2 cm, but also for tumors 2-5 cm. For resectable solitary HCC with tumors >5 cm, HR is the better choice for patients ≤65 but for patients >65, the issue of treatment choice needs to be further studied.
8 January 2025 in BMC Public Health
The objective of this research is to statistically assess the risk of cardiovascular mortality (CVM) between patients with small bowel adenocarcinoma (SBA) and the general population. Additionally, it aims to identify CVM-associated risk factors among individuals with SBA. Data obtained between 2000 and 2017 on SBA patients from the Surveillance, Epidemiology, and End Results (SEER) database were examined. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were obtained to compare CVM between patients and the general US population. To evaluate the cumulative mortality (CM) rate for all causes of death (COD), cumulative hazard curves were constructed. Two multivariate competing risk models were established to determine the independent predictors for CVM. In the cohort of 5,175 SBA patients observed for 15,068.24 person-years, a total of 205 deaths were attributed to cardiovascular disease (CVD). The overall SMR of CVM was 1.41 (95% confidence interval (CI): 1.23–1.62, P < 0.05), whereas it reached 2.99 during the early stage of latency. Additionally, independent risk factors for CVM included age, marital status, calendar year of diagnosis, disease differentiation degree, SEER stage, and chemotherapy status. SBA patients exhibited a substantially elevated risk of developing CVM compared to the general US population. During the follow-up period, the CM rate for CVM continued to rise steadily. Timely identification of high-risk groups and effective interventions to safeguard cardiovascular health significantly improve patient prognosis.